CureVac - Hauptforum Forum: Community User: NeulingImDAX

@Quasti / ich bin ganz deiner Meinung.

Wer aussteigen ist selber schuld.. Die aufgerufenen 160 können jederzeit erfüllt werden. Zugegeben: es ist eine verflixte Sache. Aber dafür kann bei Curevac Keiner was. Die halten sich bedeckt weil die fachlich besser informiert sind als so ein Jens Spahn. Der muss solche Aussagen treffen und politisch korrekt zu sein und seinen Stuhl zu retten. Warten wir nächste Woche mal ab. Ich bin froh und stolz bei Curevac zu sein. Das wird meine Aktien für die nächsten Jahre. Ist also eine andere Grundeinstellung als vielleicht viele andere haben..

eben auf ntv: Impfdosenbedarf laut WHO bei 11Milliarden..... also da ist noch nichts verloren

M610 heute 21:36 Uhr So artile link is June 10th- but it says Fakil hopes-..there is nothing at all official on SEC Listings or Curevac site Dr Sarah Fakil can not make any statement like that unless is published on SEC and Curevac website. So AS Sarah Fakih spoken on the record and published as I said- or as she spoke on TV - otherwise - everything is spurious and must be considered BS

Yes ruudi TÜBINGEN, Germany / BOSTON, USA – May 28, 2021 CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the independent Data Safety Monitoring Board (DSMB) has confirmed that the pivotal Phase 2b/3 study (HERALD) for CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV, has passed a first interim analysis at 59 adjudicated COVID-19 cases. The DSMB confirmed that there were no safety concerns for CVnCoV. As a standard procedure within a blinded trial, CureVac has no access to trial data. The trial will continue to collect sufficient data in order to conduct statistically significant efficacy analysis. The HERALD trial is conducted in an environment characterized by the spread of multiple virus strains. COVID-19 cases within the trial are currently being sequenced to provide critical complementary data to the efficacy readout. The HERALD study has enrolled approximately 40,000 participants in ten countries in Latin America and Europe. Of those participants, approximately 75% were enrolled in Latin America and 25% in Europe. The primary objective of the HERALD study is to demonstrate the efficacy of a two-dose administration of 12µg of CVnCoV in preventing COVID-19 infection of any severity in participants without prior exposure to SARS-CoV-2.

Forget the Link: https://www.google.de/amp/s/www.augsburger-allgemeine.de/politik/Corona-Impfstoff-Curevac-Zulassung-hakt-an-niedrigen-Inzidenzzahlen-id59847131-amp.html

@John: in the end of the article you find the figure 111, communicated by Sarah

Yes.. Apologies. I used the UK saying i learn that is short

@jon, you mean bs likebullshit?

Curevac next event listed ----- German Hauptstadtkongress Medizin und Gesundheit 2021 JUNE 16, 2021 Virtual Panel Discussion (German only): Medizinischer Fortschritt „Made in Germany“: Gewollt, ermöglicht und erreichbar?

i would like to know where Curevac have actually put figures on an offical news release on cases- where on the SEC filings are these cases listed.. Curevac can not communicated information on a web air link to any broker or such without making that statement official in a SEC Listing. So the number of cases curevac have to sate at some stage - everything else published his Hearsay - its leaked information 0r complete BS

BofA Securities Virtual 2021 Healthcare Conference MAY 10 - 13, 2021 Virtual Event Kempen Life Sciences Conference 2021 APRIL 28, 2021 Virtual Event

I have not found out which Investors webinar this was.

Good question! They Never did, if it’s true what Guggenheim published.

Right Jon, I forgot 31 fully sequenced of 59 total.

Again- where is the German Media on Pfizer Biontech causing Myocarditsis- Cardiomyopathy and deaths from the vaccine... https://www.fda.gov/media/150054/download